Annemarie Moseley, COO/EVP Clinical Development at BELLICUM PHARMACEUTICALS, INC (BLCM), sold 50,000 shares at $17.17 ($877K) on 2016-12-01, disclosed to the SEC on 2016-12-05.
Open-market sale of $877k BLCM by COO/EVP Clinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.17 | 14,458 | $248K | 28.3% |
| 2 | $17.17 | 14,458 | $248K | 28.3% |
| 3 | $18.04 | 10,542 | $190K | 21.7% |
| 4 | $18.04 | 10,542 | $190K | 21.7% |
| Total | $17.54 avg | 50,000 | $877K | 100% |
| Filing → |
| BLCM | SELL | 2015-07-06 | $722K | — | Filing → |